期刊文献+

定点突变提高豆豉纤溶酶的酶活力和底物特异性的研究 被引量:4

下载PDF
导出
摘要 以pBE—DFE质粒为模板,采用反向长距离PCR技术对豆豉纤溶酶(Douchi Fibrinolytic Enzyme,DFE)基因进行定点突变,使位于酶的底物结合区第156位的谷氨酸和第166位的甘氨酸分别替换为丝氨酸和丙氨酸,使临近酶的底物结合区的第169位甘氨酸残基替换为丙氨酸,获得了三个突变体E156S,G166A和G169A.将含突变基因的表达载体转化枯草杆菌WB800,构建了豆豉纤溶酶基因突变体的表达菌株WB800(E156S);WB800(G166A)和WB800(G166A).将3种表达菌株进行液体发酵培养,结果发现发酵上清液中纤溶酶的纤溶活性为460,790和900U/mL,分别是未突变酶活性(660U/mL)的70%,115%和136%;3种突变酶对合成底物的H-D-Val-Leu-Lys-pNA的酰胺水解活性是未突变酶的17%,125%和121%.
出处 《自然科学进展》 北大核心 2008年第7期826-832,共7页
  • 相关文献

参考文献11

  • 1范晓丹..新型纤溶酶得产生菌选育、发酵优化及酶学性质研究[D].华南理工大学,2006:
  • 2Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. Protein Sci, 1995, 4:337-360 被引量:1
  • 3Wells JA, Powers DB, Bott RR, et al. Designing substrate specificity by protein engineering of electrostatic interactions. Proc Natl Acad Sci USA, 1987, 84:1219-1223 被引量:1
  • 4Wright CS, Alden RA, Kraut J. Structure of subtilisin BPN' at 2.5 A. resolution. Nature, 1969, 221:235-242 被引量:1
  • 5Carter P, Nilsson B, Burnier JP, et al. Engineering subtilisin BPN ‘for site-specific' proteolysis. Proteins Struet Funet Genet, 1989, 6:240-245 被引量:1
  • 6Estell DA, Grayear TP, Miller JV, et al. Probing sterie and hydrophobie effeets on enzyme-substrate interaetions by protein engineering. Seienee, 1986, 233:659-663 被引量:1
  • 7Wells JA, Cunningham BC, Graycar TP, et al. Recruitment of substrate-specificity properties from one enzyme into a related one by protein engineering. Proc Natl Acad Sci USA, 1987, 84: 5167-5171 被引量:1
  • 8Wu SC, Yeung JC, Wong SL. Functional production and characterization of a fibrin-specific single-chain antibody fragment from Bacillus subtills: Effects of molecular chaperones and a wallbound protease on antibody fragment production. Appl Environ. Microbiol, 2002, 68:3261-3269 被引量:1
  • 9任乐民,张云升,孟雅娟.溶栓药物的研究进展[J].实用中西医结合临床,2006,6(3):91-92. 被引量:7
  • 10Kim W, Choi K, Kim Y, et al. Purification and characterization of a fibrinolytic enzyme produced from Bacillus sp. strain CK 11-4 screened from Chungkook-Jang. Appl Environ Microbiol, 1996, 62: 2482-248 被引量:1

二级参考文献13

  • 1江明性.药理学[M](第4版)[M].北京:人民卫生出版社,1996.265-266. 被引量:15
  • 2Collen D,Lijnen HR.Tissue-type plasminogen activator:a historical perspective and personal account[J].J Thromb Haemost,2004,2(4):541~546 被引量:1
  • 3Machraoui A,Jager D,Barmeyer J,et al.Efficacy and safety of APSAC in the treatment of acute myocardial infarction[J].Eur Heart J,1992,13(6):818~823 被引量:1
  • 4Wan H,Liu Z,Xia X,et al.A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo[J].Thromb Res,2000,97(3):133~141 被引量:1
  • 5Renatus M,Stubbs MT,Huber R,et al.Catalytic domain structure of vampire bat plasminogen activator:a molecular paradigm for proteolysis without activation cleavage[J].Biochemistry,1997,436(44):13 483~13 493 被引量:1
  • 6Collen D,Lijnen HR.Thrombolytic agents[J].Thromb Haemost,2005,93(4):627~630 被引量:1
  • 7Moons L,Vanlinthout I,Roelants I,et al.Toxicology studies with recombinant staphylokinase and with SY 161-P5,a polyethylene glycol-derivatized cysteine-substitution mutant[J].Toxicol Pathol,2001,29(3):285~291 被引量:1
  • 8Perler B.Thrombolyic therapies:the current state of affairs[J].J Endovasc Ther,2005,12(2):224~232 被引量:1
  • 9Nordt TK,Bode C.Thrombolysis:newer thrombolytic agents and their role in clinical medicine[J].Heart,2003,89(11):1 358~1 362 被引量:1
  • 10Inoue T,Yaguchi I,Takayanagi K,et al.A new thrombolytic agent,monteplase,is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction:initial results of the Combining Monteplase with Angioplasty (COMA) trial[J].Am Heart J,2002,144(4):E5 被引量:1

共引文献6

同被引文献79

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部